[EPZM] Epizyme, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 554.46 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 11.75 Change: 0.05 (0.43%)
Ext. hours: Change: 0 (0%)

chart EPZM

Refresh chart

Strongest Trends Summary For EPZM

EPZM is in the medium-term down -17% below S&P in 3 months. In the long-term down -42% below S&P in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops personalized therapeutics for patients with genetically defined cancers. It identifies the genetic alterations that create cancer causing genes, known as oncogenes; selects patients in whom the identified genetic alteration is found; and designs small molecule therapeutic product candidates to inhibit the oncogene. The company has two histone methyltransferases (HMT) inhibitors in clinical development for the treatment of patients with genetically defined cancers. It is conducting a Phase I clinical trial of its product candidate, EPZ-5676, an inhibitor targeting the DOT1L HMT for the treatment of acute leukemias with genetic alterations of the MLL gene; and a Phase I/II clinical trial of another product candidate, EPZ-6438, an inhibitor targeting the EZH2 HMT for the treatment of a genetically defined subtype of non-Hodgkin lymphoma and solid tumors, including INI1-deficient tumors, such as synovial sarcoma and malignant rhabdo

Fundamental Ratios
Shares Outstanding57.22 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -90.4% Sales Growth - Q/Q-91.2% P/E
P/E To EPS Growth P/S19.17 P/BV2.54 Price/Cash Per Share
Price/Free Cash Flow-14.75 ROA-43.21% ROE-50.12% ROI
Current Ratio20.83 Quick Ratio Long Term Debt/Equity Debt Ratio0.05
Gross Margin Operating Margin-378.54% Net Profit Margin-378.3% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities117.28 M Cash From Investing Activities-40.16 M Cash From Operating Activities-22.71 M Gross Profit
Net Profit-61.33 M Operating Profit-61.38 M Total Assets253.27 M Total Current Assets247.4 M
Total Current Liabilities11.88 M Total Debt1.68 M Total Liabilities34.89 M Total Revenue910 K
Technical Data
High 52 week15.12 Low 52 week5.22 Last close10.27 Last change2.6%
RSI42.98 Average true range0.54 Beta1.89 Volume427.11 K
Simple moving average 20 days-2.05% Simple moving average 50 days-13.08% Simple moving average 200 days-15.07%
Performance Data
Performance Week1.68% Performance Month-15.75% Performance Quart-18.3% Performance Half-22.43%
Performance Year9.96% Performance Year-to-date66.72% Volatility daily2.82% Volatility weekly6.31%
Volatility monthly12.93% Volatility yearly44.79% Relative Volume342.21% Average Volume648.55 K
New High New Low


2019-11-07 06:08:01 | These 36 Mass. firms made Deloitte's Technology Fast 500

2019-11-05 08:00:00 | Royalty Pharma Announces Agreement to Purchase Future Royalties on Tazemetostat from Eisai for $330 Million and a $100 Million Initial Investment in Epizyme

2019-11-04 07:00:00 | Epizyme Establishes Agreements for Up to $270 Million in Funding to Support Tazemetostat Commercialization and Pipeline Advancement

2019-10-30 07:55:11 | Epizyme EPZM Reports Q3 Loss, Tops Revenue Estimates

2019-10-30 06:30:00 | Epizyme Announces Positive Pre-NDA Meeting for Tazemetostat for Follicular Lymphoma, Pipeline Updates and Third Quarter 2019 Results

2019-10-27 14:02:06 | Hedge Funds Have Never Been This Bullish On Epizyme Inc EPZM

2019-10-15 08:37:08 | We're Hopeful That Epizyme NASDAQ:EPZM Will Use Its Cash Wisely

2019-09-08 09:30:01 | Epizyme EPZM Up 7% Since Last Earnings Report: Can It Continue?

2019-09-04 06:30:00 | Epizyme Announces Board of Director Appointments to Support Continued Evolution and Growth

2019-08-29 06:30:00 | Epizyme to Participate in Upcoming September Conferences

2019-08-16 12:32:14 | How Should Investors Feel About Epizyme, Inc.'s NASDAQ:EPZM CEO Pay?

2019-08-15 09:17:01 | Epizyme EPZM Focuses on Developing Lead Drug Tazemetostat

2019-08-12 08:37:12 | Epizyme EPZM Q2 Loss In Line, Revenues Beat Estimates

2019-08-09 07:55:11 | Epizyme EPZM Reports Q2 Loss, Tops Revenue Estimates

2019-08-09 06:30:00 | Epizyme Reports Business Progress and Second Quarter 2019 Results

2019-08-08 10:45:02 | Immunomedics IMMU Posts Wider-Than-Expected Loss in Q2

2019-08-08 10:15:02 | Horizon Therapeutics' HZNP Q2 Earnings Beat Estimates

2019-08-08 09:26:01 | Catalyst's CPRX Q2 Earnings and Revenues Beat Estimates

2019-08-06 06:30:00 | Epizyme to Present at the Wedbush PacGrow 2019 Healthcare Conference

2019-07-31 13:48:03 | Steven Cohen Charges Into Chiasma

2019-07-25 10:33:02 | Analysts Estimate Epizyme EPZM to Report a Decline in Earnings: What to Look Out for

2019-07-25 06:30:00 | Epizyme Announces FDA Filing Acceptance of New Drug Application and Priority Review for Tazemetostat for the Treatment of Epithelioid Sarcoma

2019-07-22 06:30:00 | Epizyme Strengthens Leadership Team with Appointment of Paolo Tombesi as Chief Financial Officer

2019-07-12 16:53:00 | Here's Why Epizyme Rose 103.7% in the First Half of 2019

2019-06-24 17:53:09 | Epizyme Announces Positive Interim Data on Lead Candidate

2019-06-21 07:45:00 | Epizyme Reports Updated Data from Phase 2 Trial of Tazemetostat in Patients with Relapsed or Refractory Follicular Lymphoma

2019-06-15 12:38:28 | The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs

2019-06-12 06:30:00 | Epizyme Announces Conference Call to Discuss Phase 2 Tazemetostat Follicular Lymphoma Data

2019-06-11 18:57:32 | Hedge Funds Have Never Been This Bullish On Epizyme Inc EPZM

2019-06-05 09:30:01 | Why Is Epizyme EPZM Up 10.9% Since Last Earnings Report?

2019-06-03 06:30:00 | Epizyme Reports Updated Data from Phase 2 Trial of Tazemetostat for Epithelioid Sarcoma at 2019 ASCO Annual Meeting

2019-05-31 10:46:02 | Epizyme's NDA for Tazemetostat Eyes Epithelioid Sarcoma Cure

2019-05-31 05:57:33 | Ahead of cancer conference, Epizyme CEO talks first drug, Regeneron competition

2019-05-30 06:30:00 | Epizyme Submits New Drug Application to the U.S. FDA for Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma

2019-05-30 05:51:09 | Will Epizyme to Surge Higher?

2019-05-29 06:30:00 | Epizyme to Present at Jefferies 2019 Healthcare Conference

2019-05-28 09:02:01 | Epizyme EPZM Shares Surge More Than 100% YTD: Here's Why?

2019-05-16 09:33:00 | Epizyme Announces New Tazemetostat Clinical Data to be Presented in Oral Sessions at Multiple Upcoming Medical Meetings

2019-05-09 20:10:46 | Hedge Funds Have Never Been This Bullish On Epizyme Inc EPZM

2019-05-06 07:45:11 | Epizyme EPZM Reports Q1 Loss, Tops Revenue Estimates

2019-05-06 06:35:23 | Epizyme: 1Q Earnings Snapshot

2019-05-06 06:30:00 | Epizyme Provides Business Update and Reports First Quarter 2019 Financial Results

2019-04-22 15:42:10 | If You Had Bought Epizyme NASDAQ:EPZM Stock Five Years Ago, You'd Be Sitting On A 39% Loss, Today

2019-03-28 09:30:01 | Why Is Epizyme EPZM Down 14.4% Since Last Earnings Report?

2019-03-12 10:45:00 | Epizyme Announces Closing of Concurrent Public Offerings and Full Exercise of Underwriter’s Option to Purchase Additional Shares

2019-03-08 12:14:36 | Does Epizyme, Inc.’s NASDAQ:EPZM CEO Salary Compare Well With Others?

2019-03-06 22:16:00 | Epizyme Announces Pricing of Concurrent Public Offerings of Common Stock and Series A Preferred Stock

2019-03-06 16:01:00 | Epizyme Announces Proposed Concurrent Public Offerings of Common Stock and Series A Preferred Stock

2019-03-05 06:30:00 | Epizyme Announces Presentations at Upcoming March Investor Conferences

2019-02-27 10:14:03 | Epizyme EPZM Reports Narrower-Than-Expected Loss in Q4